INTUITIVE SURGICAL INC (ISRG)
US46120E6023 - Common Stock
Overall ISRG gets a fundamental rating of 6 out of 10. We evaluated ISRG against 188 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making ISRG a very profitable company, without any liquidiy or solvency issues. ISRG is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ISRG a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year ISRG was profitable.
In the past year ISRG had a positive cash flow from operations.
In the past 5 years ISRG has always been profitable.
Each year in the past 5 years ISRG had a positive operating cash flow.
1.2 Ratios
ISRG has a better Return On Assets (12.64%) than 94.65% of its industry peers.
ISRG has a better Return On Equity (14.39%) than 90.91% of its industry peers.
ISRG has a Return On Invested Capital of 11.36%. This is amongst the best in the industry. ISRG outperforms 92.51% of its industry peers.
ISRG had an Average Return On Invested Capital over the past 3 years of 12.21%. This is above the industry average of 8.23%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.64% | ||
| ROE | 14.39% | ||
| ROIC | 11.36% |
ROA(3y)11.47%
ROA(5y)11.62%
ROE(3y)13.27%
ROE(5y)13.48%
ROIC(3y)12.21%
ROIC(5y)11.96%
1.3 Margins
The Profit Margin of ISRG (28.51%) is better than 96.79% of its industry peers.
In the last couple of years the Profit Margin of ISRG has declined.
ISRG has a better Operating Margin (26.29%) than 95.72% of its industry peers.
In the last couple of years the Operating Margin of ISRG has declined.
ISRG has a better Gross Margin (66.98%) than 72.73% of its industry peers.
In the last couple of years the Gross Margin of ISRG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.29% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.98% |
OM growth 3Y0.73%
OM growth 5Y-5.65%
PM growth 3Y1.22%
PM growth 5Y-3.58%
GM growth 3Y0.37%
GM growth 5Y-1.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ISRG is still creating some value.
Compared to 1 year ago, ISRG has more shares outstanding
The number of shares outstanding for ISRG has been increased compared to 5 years ago.
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 56.16 indicates that ISRG is not in any danger for bankruptcy at the moment.
The Altman-Z score of ISRG (56.16) is better than 100.00% of its industry peers.
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 56.16 |
ROIC/WACC1.25
WACC9.05%
2.3 Liquidity
ISRG has a Current Ratio of 4.30. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ISRG (4.30) is better than 67.91% of its industry peers.
A Quick Ratio of 3.42 indicates that ISRG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.42, ISRG is in the better half of the industry, outperforming 67.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.3 | ||
| Quick Ratio | 3.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.84% over the past year.
ISRG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.97% yearly.
Looking at the last year, ISRG shows a quite strong growth in Revenue. The Revenue has grown by 14.83% in the last year.
Measured over the past years, ISRG shows a quite strong growth in Revenue. The Revenue has been growing by 13.85% on average per year.
EPS 1Y (TTM)25.84%
EPS 3Y19.06%
EPS 5Y8.97%
EPS Q2Q%26.03%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y17.8%
Revenue growth 5Y13.85%
Sales Q2Q%16.88%
3.2 Future
ISRG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.55% yearly.
The Revenue is expected to grow by 13.39% on average over the next years. This is quite good.
EPS Next Y23.04%
EPS Next 2Y18.51%
EPS Next 3Y17.96%
EPS Next 5Y15.55%
Revenue Next Year14.99%
Revenue Next 2Y15.93%
Revenue Next 3Y15.75%
Revenue Next 5Y13.39%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 81.94, the valuation of ISRG can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ISRG indicates a somewhat cheap valuation: ISRG is cheaper than 65.78% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.96, ISRG is valued quite expensively.
Based on the Price/Forward Earnings ratio of 68.66, the valuation of ISRG can be described as expensive.
Based on the Price/Forward Earnings ratio, ISRG is valued a bit cheaper than 67.38% of the companies in the same industry.
ISRG's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 81.94 | ||
| Fwd PE | 68.66 |
4.2 Price Multiples
64.71% of the companies in the same industry are more expensive than ISRG, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ISRG is valued a bit cheaper than the industry average as 67.91% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 334.67 | ||
| EV/EBITDA | 73.96 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of ISRG may justify a higher PE ratio.
A more expensive valuation may be justified as ISRG's earnings are expected to grow with 17.96% in the coming years.
PEG (NY)3.56
PEG (5Y)9.14
EPS Next 2Y18.51%
EPS Next 3Y17.96%
5. Dividend
5.1 Amount
ISRG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTUITIVE SURGICAL INC
NASDAQ:ISRG (11/21/2024, 8:00:02 PM)
After market: 550.62 0 (0%)550.62
+8.8 (+1.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap196.12B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 81.94 | ||
| Fwd PE | 68.66 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)3.56
PEG (5Y)9.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.64% | ||
| ROE | 14.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 26.29% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.98% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.3 | ||
| Quick Ratio | 3.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)25.84%
EPS 3Y19.06%
EPS 5Y
EPS Q2Q%
EPS Next Y23.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)14.83%
Revenue growth 3Y17.8%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y